- Pure Extracts is preparing to deliver shipment of 85% pure CBD distillate
- Company proud of quality offering produced in world-class facility
- PULL uses proprietary state-of-the art, sub-critical/super-critical CO2extraction system
United Medical Equipment Business Solutions Network is a company focused on the needs of aging patients and veteran communities as well as those impacted by the COVID-19 pandemic. United is a trusted supplier of FDA-approved antibody and antigen test kits, medical equipment and personal protective equipment (“PPE”). As the world attempts to control this pandemic, it is essential to quickly identify who is infected and who has already been infected. Antibody testing determines whether or not a patient has had COVID-19 in the past while antigen testing determines whether or not a patient currently has COVID-19.
An antibody test can help determine how many people have had and recovered from COVID-19. This includes those that were asymptomatic. Since individuals are presenting various symptoms, ranging from no symptoms to full respiratory failure, symptoms alone cannot accurately confirm if someone has been infected. Antibody tests have limited use in detection but help to determine accurate case numbers and research into immunity.
The antigen rapid test allows for quick diagnosis that can help curb the spread of the virus. Antigens are a specific protein that sits on the surface of the virus. These rapid tests identify antigens when the individual is contagious. That individual can then be placed into quarantine, stopping the spread of the virus (https://ibn.fm/xB6J7).
The FDA-approved CareStart(TM) COVID-19 Antigen Rapid POC test is part of United’s answer in combating the spread of the virus. The test is administered by medical professionals to detect COVID-19 antigens. This test identifies acute infection with 88.4% sensitivity and 100% specificity, and helps provide critical answers about active infections to patients and healthcare workers alike (https://ibn.fm/Q8js4).
United moved quickly to address the growing needs created by the COVID-19 pandemic. In addition to providing test kits, COVID-19 supplies and products (https://ibn.fm/KgD8i), and PPE equipment with flexible payment options, the company has acted as a trusted senior referral source for independent living, assisted living, hospice, memory care, skilled nursing and senior care centers.
Throughout 2020 and into 2021, the elderly have been particularly vulnerable to this pandemic. United is dedicated to providing guidance for the aging population, their families, and the medical community that serves them.
For more information, visit the company’s website at www.UnitedMedSolutions.com.
NOTE TO INVESTORS: The latest news and updates relating to United Medical Equipment are available in the company’s newsroom at https://ibn.fm/UnitedMed
The rare earth elements (“REE”) market continues to be of interest for investors and governments around the world amid the heightened uncertainty due to trade restrictions out of China and increased demand for REE magnets, according to an article published by “Investing News Network” (https://ibn.fm/HfbHa). The sector provides the critical metals required for clean energy technologies and electronics that penetrates many segments of both the consumer and business spaces. As the country’s largest uranium producer and the leading critical minerals producer, Energy Fuels (NYSE American: UUUU) (TSX: EFR) has entered the REE space, committed to domestically supplying another critical mineral needed to making the new Biden Administration’s clean energy goals a reality.
After the initial hit to prices in the first half of 2020 as lockdowns and containment measures in China impacted the global supply chains, the REE space rebounded strongly in the second half of the year. And it appears that the sector’s growth will not stop there.
REEs, used in many tech devices and clean energy technologies such as smartphones, wind turbines and electric vehicles, will be critical for the sector over the next decade. Although REE’s supply and demand dynamics are still uncertain due to the pandemic, most analysts are optimistic for 2021 and beyond.
The push for the sector comes as Western countries continue to create supply chains less dependent on China. The article cites David Merriman of Roskill, a commodity research firm, who expects electric and hybrid vehicles’ drivetrains and wind turbine — which all use rare earth permanent magnets — to drive the sector’s robust growth for the remainder of the decade. For example, it is expected that REE demand for automotive applications will grow around 26.5% year-on-year in 2021.
Adamas Intelligence, a research firm focused on strategic metals and minerals, also expects demand to bounce back for nearly all end-use categories for rare earth elements in 2021. Global passenger battery EV, plug-in hybrid EV and hybrid EV sales are expected to drive the growth, increasing collectively by 20 to 40% year over year.
In April 2020, UUUU set out to penetrate the REE market as a complement to its core uranium product lines. Since the announcement of the expansion into REE business, the company has made significant strides, quickly becoming an emerging player in the space. Its initial goal is to enter the commercial REE business in H1 2021 and to supply up to 50% of U.S. rare earth demand contained in a mixed REE concentrate over the next few years.
The company also has plans to install REE separation, and perhaps additional downstream capabilities, over the next few years. The ambitious plans are to be achieved with the company’s existing infrastructure (https://ibn.fm/XhQAQ). With its expansion into the growing REE market and all debt paid off last year, the company is leveraging a robust business model that allows it to be well positioned to capitalize on the increasing momentum for the REE space.
For more information, visit the company’s website at www.EnergyFuels.com.
NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU
As the digital face of the plant-based community, PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) is taking another step to solidify its position as a one-stop shop for everything plant-based. The Company recently announced that has entered into a new collaboration with Farm Cup Coffee, an innovative coffee shop that offers organic coffee that is ethically sourced from farm owners around the world. PlantX will display and sell its houseplants at Farm Cup Coffee’s new physical location in West Hollywood, California (https://ibn.fm/TADOE).
“Displaying our indoor plants in the highly attractive Farm Cup Coffee store in West Hollywood will expand PlantX’s reach to its customers and boost our brand visibility,” said PlantX founder Sean Dollinger. “We are thrilled to collaborate with the Farm Cup Coffee team, whose passion for sustainability is echoed by PlantX’s aim to inspire people to adopt healthier, more eco-friendly lifestyles.”
PlantX anticipated that the collaboration will heighten its presence in one of L.A.’s most sought-after retail locations. The company will be displaying a wide range of indoor plants, from succulents to an exotic variety of potted flora. The carefully thought-out partnership aligns perfectly with PlantX’s commitment to supporting healthy lifestyles and community empowerment.
Indoor plants are only a fresh and beautiful introduction to what PlantX offers. The Company’s mission is to raise plant awareness in a hyper-palatable world to simplify plant-based living. PlantX lives its mission by striving to deliver the highest-quality products with the best service available.
And the PlantX product offering is widespread. From its line of indoor plants, which are now on display at Farm Cup Coffee, to its groceries, meal deliveries and plant-based gifts, the Company opens wide the potential of plants, making it both easy and appealing to discover what the world of plants can provide.
Partnering with Farm Cup Coffee in this endeavor was a no-brainer. The brand, which began in a Citroen van outfitted as a mobile and stylish coffee shop, focuses on positivity and is committed to sustainability. “We not only want you to drink good coffee, we want you to feel good drinking it too,” said Farm Cup Coffee co-founder Tony Yuan. “This harmonious partnership with PlantX at our West Hollywood location will help promote a happy and sustainable lifestyle for the local community.
With its fast-growing category verticals, PlantX offers customers across North America more than 10,000 plant-based products. In addition to offering meal and indoor plant deliveries, the company currently has plans to expand its product lines to include cosmetics, clothing and its own water brand. PlantX uses its digital platform to build a community of like-minded consumers and, most importantly, provide education.
To learn more about this company, visit www.PlantX.com, www.PlantX.ca and www.Investor.Plantx.com and view the PlantX for Plant-Based Investors.
NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that one of its wholly owned subsidiaries, Soluble Biotech, recently inked another contract with a large pharmaceutical company (https://ibn.fm/OpaJb). POAI also announced that TumorGenesis, one of its wholly owned subsidiaries, has sold media to two top research medical centers (https://ibn.fm/uXorQ).
Soluble Biotech’s contract will involve using the company’s proprietary protein formulation technology to improve the solubility and stability of a protein therapeutic destined for future clinical use.
“This opportunity may also lead to a long-term relationship whereby Soluble Biotech develops a strategic partnership to support several other therapeutics currently under development within the pharmaceutical company,” said Soluble Biotech Founder and President Dr. Larry DeLucas.
In additional company news, Predictive Oncology shared details about the sale of media to two top research medical centers. The sales by TumorGenesis, POAI’s wholly owned subsidiary, were repeat orders from hospitals in New York City and Boston, and included culturing ovarian cancer cells with specific research goals.
“We believe that this is the future of ovarian cancer research, which creates new possibilities to coming up with new treatments for this chronic and deadly disease,” said Predictive Oncology President and CEO Dr. Carl Schwartz. “In order for us to find better drugs, we have to be able to grow the right patient cells in the right media. Building the ‘living library’ of cancer cells for drug screening and discovery is the right first step.” POAI is committed to this first step and is the process of building the largest existing database of drug response data in the world.
The announcement noted that TumorGenesis can replicate ovarian cancer cells in a laboratory—outside of the patient’s body. The company has 15 ovarian cancer cell lines along with the media to grow those cells.
“These tissues, in the right TumorGenesis media, replicate not only the DNA/RNA and proteomic signatures but also replicate the histological structures that can be seen in staining, outside the patient’s body,” said TumorGenesis President and board member Richard Gabriel. The process produces invaluable information that can be used by oncologists and other cancer treatment experts to potentially identify and prescribe treatments and care for cancer patients, resulting in more positive outcomes.
The potential market for what POAI does — 3D cancer cell culture media — is expected to reach $3.2 billion sales worldwide by 2027. The space is so explosive because it currently offers the best available models for cancer drug discovery and development.
POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a road map to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of more than 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow.
For more information, visit the company’s website at www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
June 29, 2026
Disseminated on behalf of LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) and may include paid advertising. Consumers in the United States have watched prices grow at a “moderate to strong pace” in recent weeks as an apparent response to the ongoing Iran War, according to federal policy makers (https://ibn.fm/h06l8), which has a potential downstream effect […]
Rotate your device 90° to view site.